Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/FDA meeting

Executive Summary

On March 22, company execs met with Commissioner Young, CDER Director Carl Peck, MD, and CBER Director Paul Parkman, MD, to discuss Abbott's research with AIDS treatments and the approval process for drugs for life-threatening diseases. In its AIDS work, Abbott has reportedly been pursuing mapping projects similar to the Merck project publicized earlier this year. Discussion also included Abbott's research on AIDS diagnostics, including the review of the firm's HIV Antigen test, which was recommended for approval by FDA's Blood Products Advisory Committee on March 23 for diagnostic and prognostic use with AIDS patients.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel